Skip to search formSkip to main contentSkip to account menu

RS 82856

Known as: RS-82856 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

lixazinone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1988
1988
Inhibitors of cyclic AMP phosphodiesterase. 4. Synthesis and evaluation of potential prodrugs of lixazinone (N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro-2- oxoimidazo[2,1-b]quinazolin-7-yl)-oxy…
The cyclic AMP phosphodiesterase (cAMP PDE) inhibitor and cardiotonic agent lixazinone (N-cyclohexyl-N-methyl-4-[(1,2,3,5… 
1987
1987
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).
A series of analogues of the cyclic AMP phosphodiesterase (PDE) inhibitor N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2… 
1987
1987
Parenteral formulation development for the positive inotropic agent RS-82856: solubility and stability enhancement through complexation and lyophilization.
Parenteral formulation development for the positive inotropic agent N-cyclohexyl-N-methyl-4 (7-oxy-l,2,3,5-Tetrahydroimidazo[2,1… 
1987
1987
Electrochemical evaluation of the interaction between ascorbic acid and the cardiotonic drug RS-82856.
The solution phase interaction between ascorbic acid and the cardiotonic drug N-cyclohexyl-N-methyl-4(7-oxy 1,2,3,5… 
1987
1987
RS-82856, a selective phosphodiesterase inhibitor with inotropic, afterload reduction and antithrombotic properties.
1986
1986
A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
Some biochemical and pharmacological properties of a novel, potent inhibitor of cyclic AMP phosphodiesterase, N-cyclohexyl-N… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)